VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.

More than 80 percent of Kibi-Chuo residents tested for cancer-causing organic fluorine compounds in their blood had levels ...

The Kibichuo town government announced the results of its first blood tests after PFAS were detected at a water purification ...